6533b82ffe1ef96bd1295daa

RESEARCH PRODUCT

Analysis of Brain Functions in Men with Prostate Cancer under Androgen Deprivation Therapy: A One-Year Longitudinal Study.

Laura García-villodreNoura JeghalefCristina BuiguesOmar CauliJosé Rubio-brionesMaría Serrano-carrascosaVanessa Sánchez-martínezRut Navarro-martínez

subject

Longitudinal studymedicine.medical_specialty030232 urology & nephrologyGeneral Biochemistry Genetics and Molecular BiologyArticleAndrogen deprivation therapy03 medical and health sciences0302 clinical medicineInternal medicineneurotoxicityMedicineEffects of sleep deprivation on cognitive performanceCognitive declineAthens insomnia scalesleeplcsh:ScienceEcology Evolution Behavior and SystematicsDepression (differential diagnoses)cognitive functionbusiness.industryPaleontologyMoodSpace and Planetary Science030220 oncology & carcinogenesistestosteronedepressionandrogen-deprivation therapyGeriatric Depression Scalelcsh:Qbusiness

description

The relationship between cognitive decline and androgen deprivation therapy (ADT) under luteinizing hormone-releasing hormone (LHRH) analogues is unclear, and there is a scarcity of longitudinal studies considering the interaction between cognition, depressive symptoms and sleep quality in men with prostate cancer (PCa) treated with ADT. This study aimed to determine if there were differences in the scores obtained in cognitive assessment, depressive symptoms, and sleep quality after one year of ADT and determine the interrelations between sleep, mood, and cognitive status. A prospective longitudinal observational study was designed, in which a cohort of men (mean age was 70.8 years) newly treated with androgen-deprivation therapy was assessed in the first six months of treatment and 12 months later. Analysis of cognitive function by the Mini-Mental State Examination (MMSE) scores indicated a significant (p &lt

yearjournalcountryeditionlanguage
2021-03-10Life (Basel, Switzerland)
10.3390/life11030227https://pubmed.ncbi.nlm.nih.gov/33802213